COPENHAGEN, Denmark, May 21 /PRNewswire/ — Genmab A/S (CSE: GEN) announced today its fully human antibody HuMax-HepC(TM) prevented Hepatitis C virus (HCV) infection in a novel animal model. In the pre-clinical study, mice with a compromised immune system were transplanted with human liver cells (hepatocytes) and exposed to a mixture of patient-derived HCV of different genotypes
Replication of HCV was not observed in 5 of 6 mice (83%) treated with HuMax-HepC, indicating that HuMax-HepC completely prevented HCV infection. The sixth mouse was infected with HCV, but the virus was …
Read the rest of this article with a Free Trial at HighBeam Research.
Information provided by: Findarticles.com
